1James CH, Yang MH, Sehuler NY, etal. LUX-Lung 3 :A ran- domized, open-label, phase Ⅲ study of afatinib versus peme- trexed and cisplatia as [irst-line treatment for patients with ad- vanced adenocarcinoma of the lung harboring EGFR-aetivating mutations[J]. J Clin Oneol 30, 2012 (suppH abstr 7500).
2Rogerio L, Mauro Z, Jose RP, et al. A randomized phase Ⅲ trial of single-agent pemetrexed (P) versus carbopl.atin and pem- etrexed (CP) in patients with advanced non-small cell lung canc- er (NSCLC) and performance status (PS) of 2[G]. J Clin Oncol 30, 2012 (suppl; abstr 7506).
3Tony Mok, Yi Long Wu, Sumitra Thongprasert, et al. A randomized placebo-controlled phase Ⅲ study of intercalated erlo- tinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC) : FASTACT-Ⅱ [G]. J Clin Oncol 30, 2012 (suppl: abstr 7519).
4Caicun Zhou, Yi Long Wu, Xiaoqing Liu, et al. Overall survival (OS) results from OPTIMAL (CTONG0802), a phase Ⅲ trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation- positive advanced non-small cell lung cancer (NSCLC)[G]. J Clin Oncol 30, 2012 (suppl: abstr 7520).
5Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe, et al. Updated overall survival results of WJTOG 3405, a randomized phase Ⅲ trial comparing gefitinib (G) with cisplatin plus do- cetaxel (CD) as the flrst-line treatment for patients with non- small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR) [G]. J Clin Oncol 30, 2012 (suppl: abstr 7521).
6Mark G Kris, Tony Mok, Sai-Hong Ignatius Ou, et al. First- line dacomitinib (PF-00299804), an irreversible pan-HER tyro- sine kinase inhibitor, for patients with EGFR-mutant lung cane- ers[G]. J Clin Oncol 30, 2012 (suppl; abstr 7530).
7Luis Paz-Ares, Filippo De Marinis, Mircea Dediu, et al. PAR- AMOUNT: Final overall survival (OS) results of the phase Ⅲ study of maintenance pemetrexed (peru) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC)[G]. J Clin Oneol 30, 2012 (suppl: abstr 7507).
8Pasi A Janne, Alice Tsang Shaw, Jose Rodrigues Pereira, et al. Phase Ⅱ double-blind, randomized study of selumetinib (SEL)plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC)[G]. J Clin Oncol 30, 2012 (suppl, abstr 7503).
9Marina Chiara Garassino, Olga Martelli, Anna Bettini, et al. TAILOR : A phase Ⅲ trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR[G]. J Clin Oneol 30, 2012 (suppl: abstr 7501).
10Edward SKim, Marcus A. Neubauer, Alien Lee Cohn, et al. SELECTs Randomized phase Ⅲ study of docetaxel (D) or pem- etrexed (P) with or without cetuximab (C) in recurrent or pro- gressive non-small cell lung cancer (NSCLC) after platinum- based therapy[G]. J Clin Oncol 30, 2012 (suppll abstr 7502).
同被引文献77
1孙燕,石远凯.临床肿瘤内科手册[M].第5版,北京:人民卫生出版社,2008:711-717.
2Ferlay J,Shin HR,Bray F,et al.Estimates of worldwide burden of cancer in2008:GLOBOCAN2008[J].Int J Cancer,2010,127(12):2893.
3Cappuzzo F,Hirsch FR,Rossi E,et al.Epidermal grow-th factor receptor gene and protein and gefitinib sensitivi-ty in non-small-cell lung cancer[J].J Nat Cancer Insti-tute,2005,97(9):643.
4Vincent MD,Kuruvilla MS,Leighl NB,et al.Biomark-ers that currently affect clinical practice:EGFR,ALK,MET,KRAS[J].Cur Oncol,2012,19(Suppl1):S33.
5Soda M,Choi YL,Enomoto M,et al.Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer[J].Nature,2007,448(7153):561.
6Sasaki T,Rodig SJ,Chirieac LR,et al.The biology and treatment of EML4-ALK non-small cell lung cancer[J].Eur J Cancer,2010,46(10):1773.
7Bang YJ.The potential for crizotinib in non-small cell lu-ng cancer:a perspective review[J].Therap Advances MedOncol,2011,3(6):279.
8Ou SH.Crizotinib:a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond[J].Drug Design Dev Therapy,2011(5):471.
9Natale RB,Bodkin D,Govindan R,et al.Vandetan-ib versus gefitinib in patients with advanced non-small-ce-ll lung cancer:results from a two-part,double-blind,ran-domized phaseⅡstudy[J].J Clin Oncol,2009,27(15):2523.
10Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002[J].CA Cancer J Clinicians, 2005,55 : 74-108.
